N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=112 Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Atrial Fibrillation · Cardioversion · Cerebrovascular Stroke
Primary: Combined Clinical Thromboembolic or Hemorrhagic Event, Death or Silent Cerebral Thromboemboli — 9; 11 Participants
N/A N=148 PRescriptiOn PattERns Of Oral Anticoagulants
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=1,584 Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Changes in Discordant Antithrombotic Therapy — 291; 335; 277; 329 participants — p=0.02
Phase 4 N=101 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Atrial Fibrillation · Atrial Flutter
Primary: Frequency of Major Bleeding Complications in Patients Administered Dabigatran Following RF Ablation. — 1 number of events
N/A N=1,186 SDM for Stroke Prevention in Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Clinician Satisfied Encounters — 277; 400 encounters
Phase 3 N=1,426 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
Atrial Fibrillation
Primary: Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA — 170; 157…
N/A N=2,140,403 A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
Atrial Fibrillation
Primary: Incidence Rate (Per 1000 Participant-years) of Stroke in Non-valvular Atrial Fibrillation (AF) Participants Exposed to Oral Anticoagulation (OAC) and Unexposed to OAC…
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
Phase 4 N=1,500 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Atrial Fibrillation
Primary: Number of Participants With Acute Stroke Event — 0; 6 participants — p=0.0151
Phase 3 N=18,201 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period — 159; 173…
N/A N=492 Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
Stroke, Acute
Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001
N/A N=2,506 D-dimer Assay for the Exclusion of Intra-atrial Thrombus Risk Before Ablation of Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Patients With Atrial Thrombus Diagnosed by Transoesophageal Ultrasound — 48 Participants
N/A N=73,989 Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
Non-valvular Atrial Fibrillation
Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…
N/A N=34 Decision Aids for Patients With Nonvalvular Chronic Atrial Fibrillation (DA4AFib)
Atrial Fibrillation
Primary: Interview Process — 34 Participants
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
N/A N=349 WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
Atrial Fibrillation · Aortic Valve Stenosis
Primary: Composite of All-cause Mortality, Stroke and Bleeding — 60; 64 Participants
Phase 4 N=4,614 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Acute Coronary Syndromes
Primary: The Rate of International Society on Thrombosis and Haemostasis (ISTH) Major or Clinically Relevant Non-Major (CRNM) Bleeding With Apixaban Versus Vitamin K Antagonist…
N/A N=12 Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation
Atrial Fibrillation
Primary: Gaps Days Between Prescription Refills for Dabigatran, Rivaroxaban, and Apixaban — 43; 51; 41; -5 days
Phase 2 N=195 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Ischemic Stroke · Transient Ischemic Attack
Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants
N/A N=25 Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation
Atrial Fibrillation · Stroke
Primary: Quality of Life RAND 36-Item Health Survey — 33; 46.25; 49.5; 49.16 units on a scale — p=0.03
Phase 2 N=949 Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation
Nonvalvular Atrial Fibrillation
Primary: Bleeding Events — 18; 8; 22; 17 Participants
N/A N=102 Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus
Atrial Fibrillation
Primary: Time to Imaging — 28.1; 7.1 hours
Phase 4 N=154 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
Atrial Fibrillation · End Stage Renal Disease
Primary: Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding — 21; 16 Participants…
Phase 3 N=14,236 An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
Atrial Fibrillation · Stroke · Embolism
Primary: The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority) — 188; 241 Patients — p=<0.001
Phase 3 N=88 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Transient Ischemic Attack · Stroke · Atrial Fibrillation
Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants
N/A N=243 Atrial Fibrillation Health Literacy and Information Technology Trial
Atrial Fibrillation · Familial Atrial Fibrillation · Arrythmia, Cardiac
Primary: Proportion of Days Covered — 1.0; 0.9 Proportion of days covered — p=0.22
Phase 3 N=7,554 Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
Atrial Fibrillation · Vascular Risk
Primary: First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per…
Phase 2 N=523 Long-term Safety in Atrial Fibrillation Patients
Persistent or Permanent Nonvalvular Atrial Fibrillation
Primary: Bleeding: Number of Patients With Any Bleeding Event, During Treatment Period — 55; 56 Participants